ミネソタ州における膠芽腫の臨床試験
ミネソタ州内の拠点で、膠芽腫に関する19件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- Mayo Clinic in Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Allina Health Systems/Abbott Northwestern Hospital, Minneapolis
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT03970447GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07301268REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
- University of Minnesota Radiation Oncology, Minneapolis
被験者募集中
18歳以上 · 全性別 · 2026/09/21更新 · NCT07831772SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Mayo Clinic - Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
- Mayo Clinic in Rochester, Rochester
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07076472Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/18更新 · NCT04047264Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/17更新 · NCT07091864A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
- Mayo Clinic in Rochester, Rochester
被験者募集中
18歳以上 · 全性別 · 2026/08/10更新 · NCT07074756Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Mayo Clinic, Rochester
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/07/17更新 · NCT07225621Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
- Mayo Clinic in Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/24更新 · NCT07468136Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- Mayo Clinic, Rochester
被験者募集中第1/2相
19歳以上 · 全性別 · 2026/06/08更新 · NCT06011109First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
- Elizabeth C. Neil, MD, Minneapolis
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/05/01更新 · NCT07560865ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/21更新 · NCT05917145A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
- Mayo Clinic Hospital, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/14更新 · NCT07185880Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Cancer Center, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- Mayo Clinic, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/12更新 · NCT05465954SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
- Mayo Clinic, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2024/11/19更新 · NCT06160206ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。